[HTML][HTML] Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a …
EL Simpson, JR Parnes, D She, S Crouch… - Journal of the American …, 2019 - Elsevier
Background Tezepelumab (AMG 157/MEDI9929), a first-in-class monoclonal antibody,
targets thymic stromal lymphopoietin, a cytokine that is implicated in the pathogenesis of
atopic dermatitis (AD). Objective We sought to evaluate the efficacy and safety of
tezepelumab in adults with moderate to severe AD. Methods In this phase 2a study
(NCT02525094), 113 patients were randomized 1: 1 to subcutaneous tezepelumab 280 mg
or placebo every 2 weeks, plus class 3 topical corticosteroids (TCS). The primary endpoint …
targets thymic stromal lymphopoietin, a cytokine that is implicated in the pathogenesis of
atopic dermatitis (AD). Objective We sought to evaluate the efficacy and safety of
tezepelumab in adults with moderate to severe AD. Methods In this phase 2a study
(NCT02525094), 113 patients were randomized 1: 1 to subcutaneous tezepelumab 280 mg
or placebo every 2 weeks, plus class 3 topical corticosteroids (TCS). The primary endpoint …